In a new clinical trial, stem cell therapy has been shown to ‘reset’ the immune system and prevent disease progression in patients with multiple sclerosis (MS). Autologous hematopoietic stem cell transplantation (AHSCT) prevented symptoms of severe MS from worsening for 5 years in 46% of patients tested, indicating that this could be a promising new treatment avenue, particularly for patients who otherwise do not respond to other therapies. However, researchers warn that the treatment involves aggressive chemotherapy that carries significant risk.
Restricted Content / Members Only
You cannot view this content because It is available to members only. Please Login or Register to view this area.